Tezspire

(Tezepelumab)

Phase 3Monoclonal antibody

Tezspire is a monoclonal antibody that works as a Thymic Stromal Lymphopoietin Inhibitor.[2] It is being investigated across 21 indications, with its most advanced program in Phase 3.[1]

Tezspire is one of 356 biologic programs targeting Atopic Eczema. It is currently in Phase 3.

Indications

Total Trials

Active Trials

355

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atopic EczemaActive, not recruiting

SinusitisUnknown

Airway ObstructionUnknown

Atopic AsthmaActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Allergic RhinitisActive, not recruiting

Allergic AsthmaActive, not recruiting

Granulomatosis With PolyangiitisActive, not recruiting

Chronic RhinosinusitisActive, not recruiting

Allergic DiseaseActive, not recruiting

Atopic EczemaPhase 2

Active, not recruiting

SinusitisPreclinical

Unknown

Airway ObstructionPreclinical

Unknown

Atopic AsthmaPhase 1

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 3

Active, not recruiting

Allergic RhinitisPhase 2

Active, not recruiting

Allergic AsthmaPhase 2

Active, not recruiting

Granulomatosis With PolyangiitisPhase 2

Active, not recruiting

Chronic RhinosinusitisPhase 3

Active, not recruiting

Allergic DiseasePhase 1

Active, not recruiting

Showing 10 of 21 indications

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Tezspire

AstraZeneca

Phase 3

1 2

Fluzone

Sanofi

Preclinical

16 3

Fluzone

GSK

Preclinical

37 4

Trexall

Alnylam Pharmaceuticals

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

COMIRNATY

Pfizer

Preclinical

1 7

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 8

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 9

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Fluvirin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Asthma

NCT06705764

Phase 2Active, not recruiting

Allergic Rhinitis

NCT06189742

Not yet recruiting

Asthma

NCT06438913

Q1 2027

Phase 3Active, not recruiting

Eosinophilic Esophagitis

NCT05583227

Q2 2027

Recruiting

Asthma

NCT06948396

Q1 2028

Phase 3Recruiting

Chronic Rhinosinusitis With Nasal Polyps

NCT07520162

Clinical

Trials by Indication[1]

Asthma15 trials

Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe Asthma

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07302516·636 enrolled

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT05329194·287 enrolled

Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

Terminated· AstraZeneca logo

AstraZeneca·Phase 3·NCT05398263·125 enrolled

Show 12 more trials

Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab

Not yet recruiting·UUniversity Hospital, Montpellier·Phase 3·NCT07013123·38 enrolled

Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT03688074·116 enrolled

Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT03706079·951 enrolled

Patient Characteristics, Treatment Patterns and Outcomes of Patients With Severe Asthma Treated With Tezepelumab in the Real World; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres

Completed· AstraZeneca logo

AstraZeneca··NCT06455462·352 enrolled

Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT03406078·150 enrolled

Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT05274815·305 enrolled

Tezepelumab Treatment in Korean Severe Asthma Patients

Not yet recruiting·—··NCT06438913·100 enrolled

Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe Asthma

Completed·MMcMaster University·Phase 3·NCT05280418·27 enrolled

Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy

Recruiting· AstraZeneca logo

AstraZeneca··NCT06948396·300 enrolled

Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)

Not yet recruiting·UUniversity of Alberta·Phase 4·NCT06705764·100 enrolled

Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04673630·18 enrolled

A Multicentre, Randomised, Double-Blind, Parallel-Group Placebo-Controlled, Phase 3, Efficacy and Safety Study of Tezepelumab in 5 to < 12 Year Old Children With Severe Uncontrolled Asthma (HORIZON)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06023589·231 enrolled

Atopic Dermatitis2 trials

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

Terminated· Amgen logo

Amgen·Phase 2·NCT03809663·251 enrolled

Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis

Completed· Amgen logo

Amgen·Phase 1·NCT00757042·78 enrolled

Chronic Rhinosinusitis With Nasal Polyps2 trials

Effect of Tezepelumab on Barrier Function in Severe Asthmatic Patients With and Without Comorbid Chronic Rhinosinusitis With Nasal Polyps

Not yet recruiting·MMedical University of Vienna·N/A·NCT07046117·20 enrolled

BIFANG: A Multicentre, Single-Arm, Phase 3b Study to Assess Nasal Polyps Score and Symptoms in Chinese Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07520162·230 enrolled

Chronic Obstructive Pulmonary Disease (COPD)2 trials

A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06878261·990 enrolled

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06883305·990 enrolled

Chronic Spontaneous Urticaria1 trial

Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria

Completed· Amgen logo

Amgen·Phase 2·NCT04833855·183 enrolled

16 more indications

Cardiac1 trial

Tezspire Cardiac Events PASS

Recruiting· AstraZeneca logo

AstraZeneca··NCT06951867·16,640 enrolled

Allergic Rhinitis1 trial

Tezepelumab in Allergic Rhinitis and Asthma Study (TEZARS)

Active, not recruiting·—·Phase 2·NCT06189742·19 enrolled

Inflammation1 trial

Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD

Recruiting·AAsger Sverrild·Phase 2·NCT05507242·80 enrolled

Influenza1 trial

Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT05062759·70 enrolled

Allergic Asthma1 trial

Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma

Unknown status·MMcMaster University·Phase 2·NCT05740748·34 enrolled

Eosinophilic Esophagitis1 trial

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05583227·368 enrolled

Atopic Asthma1 trial

Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma

Completed· Amgen logo

Amgen·Phase 1·NCT01405963·31 enrolled

Granulomatosis with Polyangiitis1 trial

Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis

Enrolling by invitation·IImperial College London·Phase 2·NCT06230354·66 enrolled

Adult1 trial

Safety Study of Tezepelumab (AMG 157) in Healthy Adults

Completed· Amgen logo

Amgen·Phase 1·NCT00972179·49 enrolled

Adult Subject1 trial

A Study to Evaluate the Pharmacokinetics of Tezepelumab After Being Delivered by an Accessorized Pre Filled Syringe or Autoinjector Compared With Vial and Syringe in Healthy Adult Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03989544·315 enrolled

COPD Exacerbation1 trial

Tezepelumab COPD Exacerbation Study

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT04039113·337 enrolled

Chronic Rhinosinusitis1 trial

Opening the "Black Box" on Tezepelumab's Effect on Chronic Rhinosinusitis With Severe Asthma

Not yet recruiting·—·Phase 3·NCT06740045·10 enrolled

Airway Remodelling, Asthmatic1 trial

REVErsing Airway Remodelling With Tezepelumab : a Protocol for a Double-blind Randomized Controlled Trial for Patients With Asthma

Completed·UUniversity Hospital, Montpellier·Phase 3·NCT05651841·90 enrolled

Peanut Allergy1 trial

Efficacy of Tezepelumab in Peanut Oral Immunotherapy: a Double-Blind, Randomized, Placebo-Controlled Trial

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT07015996·62 enrolled

Severe Asthma1 trial

TAPER: A Prospective, Interventional, Multicentre, Single-Arm, Phase 3b Study to Evaluate the Step-Down of Maintenance Therapy in Patients With Severe Asthma Treated With Tezepelumab

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07363642·400 enrolled

Unspecified1 trial

Tezepelumab Home Use Study

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT03968978·216 enrolled

Sources

References

[1]
ClinicalTrials.gov — 38 trial records for Tezepelumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tezepelumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tezepelumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Thymic Stromal Lymphopoietin Inhibitor[2]
Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

Tezspire

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q1 2028

Trials by Indication[1]

Asthma15 trials

Atopic Dermatitis2 trials

Chronic Rhinosinusitis With Nasal Polyps2 trials

Chronic Obstructive Pulmonary Disease (COPD)2 trials

Chronic Spontaneous Urticaria1 trial

Cardiac1 trial

Allergic Rhinitis1 trial

Inflammation1 trial

Influenza1 trial

Allergic Asthma1 trial

Eosinophilic Esophagitis1 trial

Atopic Asthma1 trial

Granulomatosis with Polyangiitis1 trial

Adult1 trial

Adult Subject1 trial

COPD Exacerbation1 trial

Chronic Rhinosinusitis1 trial

Airway Remodelling, Asthmatic1 trial

Peanut Allergy1 trial

Severe Asthma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News